Dr. Li is currently a Research Associate Professor in the Department of Physiology and the Tulane Hypertension and Renal Center of Excellence at Tulane University School of Medicine. She joined Tulane University from the Department of Pharmacology and Toxicology at the University of Mississippi Medical Center in Jackson, Mississippi, where she was a Senior Research Scientist. Dr. Li graduated with a medical degree (equivalent to M.D. in the USA) from Guangxi Medical University, Nanning, China in 1983, and with a research Master of Science (M.Sc.) degree in Cardiovascular Pharmacology from the Department of Pharmacology at Monash University in Melbourne, Australia in 1996, where Dr. Li studied the cardiovascular pharmacology of nonpeptide angiotensin II receptor antagonists and their pharmacological effects on regional hemodynamics, including their antihypertensive actions, renal, mesenteric, and hindquarter vascular resistance and compliances. She undertook further postdoctoral training in genomic and molecular pharmacology as a Research fellow in the Department of Pharmacology at the University of Michigan, Ann Arbor from 2002-2003. Dr. Li was subsequently appointed to an Assistant Staff Investigator in the Division of Hypertension and Vascular Research at Henry Ford Hospital, focusing on studying on the novel roles of circulating (endocrine or tissue-to-tissue), paracrine (cell-to-cell), and intracrine (intracellular) angiotensin II and its receptor signaling transduction mechanisms in the development of hypertension and kidney injury from 2004 to 2010. She moved to the Department of Pharmacology and Toxicology at the University of Mississippi Medical Center in 2010 and worked as a Senior Scientist on the roles of circulating, paracrine, and intracrine angiotensin II in the regulation of blood pressure and proximal tubular function using novel cultured proximal tubule cells and transgenic mutant mouse models. Dr. Li has published 53 high impact articles with 6 original articles being selected for an editorial commentary, 3 for highlighting on a journal’s color cover, 2 for Innovative Methodology articles, 2 for recommendation by the Faculty of 1000, and 3 as a journal’s featured article in this research field. Over her research career, she has been recognized by an Australian Academy of Science Young Investigator Travel Award, Glasgow, International Society of Hypertension (1996); New Investigator Award at the 59th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, New Investigator Award at the 62nd Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, and the Kidney Council New Investigator Award at the 63rd Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, respectively. Dr. Li’s research is currently supported by grants from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
As a Senior Co-Investigator, Dr. Li is interested in studying the roles of endocrine (tissue-to-tissue), paracrine (cell-to-cell), and intracrine (endosomal, mitochondrial and nuclear) angiotensin II (ANG II) and its G protein-coupled receptor (GPCR) signal mechanisms in the proximal tubules of the kidney and blood pressure control. Supported by grants from the NIDDK, the laboratory currently investigates: 1) the molecular and signaling mechanisms by which circulating and paracrine ANG II is taken up by the proximal tubule of the kidney to act as an intracellular peptide; 2) high...
Publications for Dr. Xiao Li.
